New research finds chronic pain is five times more common in patients with Parkinson’s disease compared to age-matched ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

If you’ve been wanting to add a retinol into your skin care routine but don’t know where to start, we tapped a few experts ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

The Phase II trial comes as the US Food and Drug Administration grants an investigational new drug application for cannabis ...

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

The following is a summary of “Spaced Transcranial Direct Current Stimulation for Major Depression,” published in the January ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...